Q3 2019 Earnings Call
Opportunity for a medicine that preferentially stimulates expansion of T regulatory cells. We are currently studying nektar threefifty.
Eight in a phase one be multiple ascending dose study in lupus patients.
Which is expected to complete by the end of the year.
We plan to some.